These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1680 related items for PubMed ID: 18355499

  • 21. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
    Motoyama S, Sugiyama T, Ueno Y, Okamoto H, Takasawa S, Nanjo H, Watanabe H, Maruyama K, Okuyama M, Ogawa J.
    Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
    [Abstract] [Full Text] [Related]

  • 22. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
    Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM.
    J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1579-86. PubMed ID: 15173710
    [Abstract] [Full Text] [Related]

  • 23. [Chemoradiotherapy followed by surgery in treatment of locally advanced esophageal carcinoma: a phase II trial].
    Fu JH, Rong TH, Li XD, Hu Y, Ou W, Hu YH, Li Q.
    Ai Zheng; 2004 Nov; 23(11 Suppl):1473-6. PubMed ID: 15566661
    [Abstract] [Full Text] [Related]

  • 24. Neoadjuvant therapy for esophageal cancer: standard of care or elusive myth?
    Boyle MJ, Franceschi D, Robinson DS, Livingstone AS.
    Am Surg; 2001 Oct; 67(10):956-65. PubMed ID: 11603553
    [Abstract] [Full Text] [Related]

  • 25. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
    Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H, Siewert JR.
    Cancer; 2006 May 15; 106(10):2119-27. PubMed ID: 16607651
    [Abstract] [Full Text] [Related]

  • 26. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer.
    Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, Mori M, Doki Y.
    J Surg Oncol; 2009 Nov 01; 100(6):442-6. PubMed ID: 19653262
    [Abstract] [Full Text] [Related]

  • 27. Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy.
    Makary MA, Kiernan PD, Sheridan MJ, Tonnesen G, Hetrick V, Vaughan B, Graling P, Elster E.
    Am Surg; 2003 Aug 01; 69(8):693-700; discussion 700-2. PubMed ID: 12953828
    [Abstract] [Full Text] [Related]

  • 28. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.
    Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M.
    Ann Surg Oncol; 2008 Oct 01; 15(10):2661-7. PubMed ID: 18389322
    [Abstract] [Full Text] [Related]

  • 29. Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy.
    McKenzie S, Mailey B, Artinyan A, Metchikian M, Shibata S, Kernstine K, Kim J.
    Ann Surg Oncol; 2011 Feb 01; 18(2):551-8. PubMed ID: 20839062
    [Abstract] [Full Text] [Related]

  • 30. Role of neoadjuvant therapy for esophageal adenocarcinoma.
    Ku GY, Ilson DH.
    Surg Oncol Clin N Am; 2009 Jul 01; 18(3):533-46. PubMed ID: 19500742
    [Abstract] [Full Text] [Related]

  • 31. [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
    Han JQ, Liu Q, Liang RX, Qu FS, Yan TX, Sun YH, Li XQ.
    Zhonghua Zhong Liu Za Zhi; 2007 Jun 01; 29(6):470-3. PubMed ID: 17974287
    [Abstract] [Full Text] [Related]

  • 32. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM.
    Ann Surg Oncol; 2008 Oct 01; 15(10):2894-902. PubMed ID: 18663531
    [Abstract] [Full Text] [Related]

  • 33. Management for patients with advanced T4 epidermoid carcinoma of the esophagus.
    Wang LS, Chi KH, Hu MH, Fahn HJ, Huang MH.
    J Surg Oncol; 1996 May 01; 62(1):22-9. PubMed ID: 8618396
    [Abstract] [Full Text] [Related]

  • 34. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation.
    Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT.
    Cancer; 2005 Apr 01; 103(7):1347-55. PubMed ID: 15719440
    [Abstract] [Full Text] [Related]

  • 35. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
    Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, Hamilton SR, Wu TT.
    Clin Cancer Res; 2005 Mar 15; 11(6):2229-36. PubMed ID: 15788671
    [Abstract] [Full Text] [Related]

  • 36. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent.
    Mariette C, Piessen G, Briez N, Triboulet JP.
    Ann Surg; 2008 Feb 15; 247(2):365-71. PubMed ID: 18216546
    [Abstract] [Full Text] [Related]

  • 37. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity.
    Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, Walsh GL, Putnam JB, Komaki R, Ajani JA, Roth JA.
    Ann Thorac Surg; 2005 Feb 15; 79(2):391-7; discussionn 391-7. PubMed ID: 15680801
    [Abstract] [Full Text] [Related]

  • 38. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
    Kim DW, Blanke CD, Wu H, Shyr Y, Berlin J, Beauchamp RD, Chakravarthy B.
    Int J Radiat Oncol Biol Phys; 2007 Feb 01; 67(2):397-404. PubMed ID: 17097833
    [Abstract] [Full Text] [Related]

  • 39. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study.
    Hsu FM, Lin CC, Lee JM, Chang YL, Hsu CH, Tsai YC, Lee YC, Cheng JC.
    J Surg Oncol; 2008 Jul 01; 98(1):34-41. PubMed ID: 18449912
    [Abstract] [Full Text] [Related]

  • 40. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK, Law S, Kwong DL, Chan KW, Lam AK, Wong KH.
    Ann Surg Oncol; 2010 Aug 01; 17(8):2184-92. PubMed ID: 20217248
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 84.